[디멘시아뉴스] 반쪽짜리 치매약 '아두카누맙' 허가 결정, Fda 선택은?
Synopsis
디멘시아뉴스 홈페이지 http://www.dementianews.co.kr/
![[디멘시아뉴스] FDA, 치매약 아두카누맙 심사기간 3개월 연장](https://i.ytimg.com/vi/Ni6WapguxmI/hqdefault.jpg?sqp=-oaymwE2COADEI4CSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARg-IGQocjAP&rs=AOn4CLBCfEezJUr2r7DdNa6vLoLvVPKBDg)
![[디멘시아뉴스] FDA 자문위 소속 의사, 아두카누맙 승인에 재차 반대](https://i.ytimg.com/vi/agdUlduof_Y/hq720.jpg?sqp=-oaymwE2CNAFEJQDSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARhbIFsoWzAP&rs=AOn4CLDvyrebhZtATyzEZR62ITnNvCCWzA)
![[디멘시아뉴스] 아두카누맙 허가 먹구름...FDA 자문회의, 유효성 부정](https://i.ytimg.com/vi/F9stKGut1TU/hq720.jpg?sqp=-oaymwEcCNAFEJQDSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLA_MsQXNse22wCK5XGZFvQg-hb4PA)
![[디멘시아뉴스] 치매약 아두카누맙 적정가 연간 2,500~8,300달러](https://i.ytimg.com/vi/kJW8JUTHouo/hq720.jpg?sqp=-oaymwE2CNAFEJQDSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARhlIGUoZTAP&rs=AOn4CLBDVmWKK4sAxpEqxUCb2R3NNIn_vg)
![[디멘시아뉴스] 아두카누맙, 안전성·유효성 재입증 위한 임상3상 진행](https://i.ytimg.com/vi/gecFU1oFOiM/hqdefault.jpg?sqp=-oaymwE2COADEI4CSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARhlIGUoZTAP&rs=AOn4CLBQiHHuOqdzjytaQAj0NJQTEnkzlw)
![[디멘시아뉴스] 美 FDA, 알츠하이머치료제 '아두헴' 시판 승인](https://i.ytimg.com/vi/WV1ItNXuY-I/hqdefault.jpg?sqp=-oaymwE2COADEI4CSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARg_IF0oZTAP&rs=AOn4CLD50-TThgPpwY6KzItkyCt4OKTfpQ)
![[디멘시아뉴스] 릴리, 치매약 도나네맙 허가 신청...내년 승인 기대](https://i.ytimg.com/vi/1d818iskKVU/hqdefault.jpg?sqp=-oaymwE2COADEI4CSFXyq4qpAygIARUAAIhCGAFwAcABBvABAfgB1AaAAuADigIMCAAQARhlIGUoZTAP&rs=AOn4CLDwbD5I84g-oKhQoHRwbEmoNdg-UQ)
![레카네맙, 아두카누맙과 다를까...美 보험 등재 '1차 관문'/[IPO 프리보드]/한국경제TV뉴스](https://i.ytimg.com/vi/AUYAHLM1PEw/hq720.jpg?sqp=-oaymwEcCNAFEJQDSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLC1lGT7uPRrQWiiXWrXakbkqWco3g)
Download Options
Choose a download method below. All links open in new tabs.
| Service | Features | Action |
|---|---|---|
| Ssvid |
MP4 & MP3 • HD Quality • Browser Extension Available
|
Download |
| SaveFrom |
MP4 & MP3 • HD Quality • Browser Extension Available
|
Download |
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.